Phase II Study of Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)
Latest Information Update: 13 Jul 2022
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- 21 Jun 2022 Status changed from completed to discontinued.
- 25 Mar 2022 Status changed from recruiting to completed.
- 14 Oct 2021 Planned End Date changed from 1 Apr 2022 to 1 Apr 2024.